New hope for tough blood cancers: drug combo shows promise
NCT ID NCT02500407
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This study tested a new drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with certain blood cancers (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia) that returned or didn't respond to prior treatment. The goal was to find the safest dose and see how well it works. About 713 adults took part, and the study looked at side effects, tumor shrinkage, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Cancer Institute
London, EC1A 7BE, United Kingdom
-
Clínica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hospital Universitario La Paz
Madrid, 280146, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, 08035, Spain
-
Icon Cancer Care South Brisbane
South Brisbane, Queensland, 4101, Australia
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Klinikum der Universität München, Campus Großhadern
München, 83177, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York, 10604, United States
-
Monash Health Clinical Trial Pharmacy department
Clayton, Victoria, 3168, Australia
-
New York Uni Medical Center
New York, New York, 10016, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Rocky Mountain Cancer Center
Denver, Colorado, 80218, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
-
Royal Marsden Hospital;Institute of Cancer Research
Sutton, SM2 5PT, United Kingdom
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sansum Medical Clinic, Inc.
Santa Barbara, California, 93105, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
St. Vincent's Hospital Melbourne
Fitzroy, South Australia, 3065, Australia
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Perth Blood Institute
Nedlands, Western Australia, 6009, Australia
-
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, 55101, Germany
-
Universitatsklinikum Koln
Cologne, 50931, Germany
-
University of California San Diego Moores Cancer Center
La Jolla, California, 92093-0698, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19103, United States
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon, 97477, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06510, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.